(Total Views: 207)
Posted On: 01/23/2017 12:58:42 PM
Post# of 72447
Looks like AF learned to report "alternative facts" from the Trump administration last weekend.
AF: Cellceutix has not told investors about the Prurisol-related liver toxicity seen in its Phase II study.
CTIX: One Serious Adverse Event (preferred term “hepatic enzyme increased”) reported in 50 mg dose group. Liver function test increases reported as AEs, with following frequency: Aspartate Aminotransferase (AST) increased, 4 AEs; Alanine Aminotransferase (ALT) increased, 3 AEs; Hepatic enzyme increased, 1 AE
AF: Additional patients treated with the higher doses of Prurisol also reported increases in liver enzymes, some greater than two times the upper limit of normal, according to the Sept. 19 presentation of the Phase 2 study results.
CTIX: Elevations in ALT and/or AST do not appear dose related
If liver toxicity was dose-related, why didn't it exist in the 100 mg and the 200 mg arms?
AF: Cellceutix has not told investors about the Prurisol-related liver toxicity seen in its Phase II study.
CTIX: One Serious Adverse Event (preferred term “hepatic enzyme increased”) reported in 50 mg dose group. Liver function test increases reported as AEs, with following frequency: Aspartate Aminotransferase (AST) increased, 4 AEs; Alanine Aminotransferase (ALT) increased, 3 AEs; Hepatic enzyme increased, 1 AE
AF: Additional patients treated with the higher doses of Prurisol also reported increases in liver enzymes, some greater than two times the upper limit of normal, according to the Sept. 19 presentation of the Phase 2 study results.
CTIX: Elevations in ALT and/or AST do not appear dose related
If liver toxicity was dose-related, why didn't it exist in the 100 mg and the 200 mg arms?
(6)
(0)
